Clinical trial
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
NCT00045669 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00045669 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Salivary Gland Cancer |
| Official title | A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Enrollment | 16 |
| Start date | Jul 1, 2002 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 15, 2019 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: